Latest Articles and Analysis

Mpox emergency response analysis and lessons for future equitable public health crises.

Celebrity HIV misinformation directly impacts testing rates and perpetuates harmful stigma.

Declining HCV infections but persistent treatment barriers and disparities remain.

Strategies to address HIV-related stigma and its role in the epidemic.

Transgender communities face elevated HIV risk; stigma and discrimination undermine prevention.

Congenital syphilis cases tripled since 2017; integrated response including testing and education needed.

SAMHSA releases Harm Reduction Framework for federal substance use programming and community approaches.

House appropriations proposes deep cuts to HIV/HCV funding including elimination of EHE initiative.

CDC report: HCV persists despite decade-old cure due to payer barriers and screening failures.

Opioid settlement funds allocation overview: oversight and community impact considerations.

Mid-year policy update covering Medicaid unwinding, ACA preventive care, and public health funding.

New MPOX clusters signal resurgence; insufficient vaccine coverage in marginalized communities.

STI surveillance report shows rising syphilis and congenital syphilis amid workforce shortages.

Xylazine contamination of drug supply demands harm reduction response including safe consumption sites.

HIV-MPV co-infection rates between 28-51% indicate need for targeted interventions and provider education.

Nevada expands syringe vending machines with naloxone, fentanyl strips; anonymity critical for uptake.

State-level MPV surveillance: Black Americans overrepresented in Southern states amid reporting gaps.

2022-2023 respiratory season tracking flu, COVID-19, and RSV with severe early indicators.

Patients face multiple monkeypox barriers: disorganized state websites, limited vaccine access, reporting gaps.

Stigma drives opposition to harm reduction programs like safe consumption sites despite strong evidence.